Open in PodwiseOpen

Podcast cover

BioCentury · Business

BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Episodes

Ep. 330 - China's Innovation Moment

Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors

Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers

Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg

Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A

Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund

Ep. 324 - Genmab, GSK and Drug Pricing

Ep. 323 - Agentic AI: From New Targets to the Clinic

Ep. 322 - Takeaways from BioCentury Grand Rounds Europe

Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus

Ep. 320 - U.K. Biotech, U.S.-China, Insmed

Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more

Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines

Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat

Ep. 316 - Trends in Pharma Deals

Ep. 315 - China Speed: Data, Deals, First in Class

Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecur

Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer

Ep. 312 - Biotech Progress Report

Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More

Page 4

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise